Rinvoq (upadacitinib) for vitiligo: evidence, approval, and risks

Rinvoq is a systemic treatment with continuing screening, laboratory, follow-up, and access burden. EU authorization does not guarantee local availability or reimbursement, and off-label US or UK use may face additional prescribing and coverage barriers.⌁ Evidence⌁ Evidence⌁ Evidence

A registered Viti-Up substudy is evaluating Rinvoq with narrowband UVB in selected inadequate responders, but no combination result was posted when reviewed. Evidence does not yet establish that adding phototherapy improves the benefit–risk balance.⌁ Evidence

The evidence does not establish equal response across face, hands, feet, or every other body area, and the phase 3 numbers remain sponsor-reported rather than peer reviewed. Patient stories may reveal burden and priorities, but they cannot establish effectiveness, safety, or who should take a systemic medicine.⌁ Evidence⌁ Evidence⌁ Evidence

The European Commission authorization sets the vitiligo dose at 15 mg upadacitinib by mouth once a day. It applies to adults and adolescents age 12 and older who weigh at least 30 kg. The two phase 3 studies assessed their co-primary results at week 48 - about eleven months after starting, not sooner. AbbVie’s own release describes response continuing to build across that full period rather than appearing early. Do not read any of this as a personal dose or schedule. A regulator record and a label are not a prescription, and neither am I.⌁ Evidence⌁ Evidence⌁ Evidence

AbbVie’s own cost page lists a wholesale acquisition cost of $7,090.41 for a 30-day Rinvoq supply, as of January 6, 2026. That is the list price before insurance, discount, or any program applies, and it is not specific to the 15 mg vitiligo dose. For eligible patients with commercial insurance, the RINVOQ Complete Savings Card can bring the monthly cost to $0, subject to a monthly maximum and other program terms. It excludes anyone with Medicare, Medicaid, or another government plan. AbbVie’s myAbbVie Assist program can provide the medicine at no cost to qualifying uninsured or underinsured patients who meet AbbVie’s income and other criteria. AbbVie also gives example Medicaid and Medicare Part D costs. Medicaid runs $8 or less a month; Part D runs $0 to $2,100, depending on the coverage phase. Those are AbbVie’s own examples, not a quote for any specific plan.⌁ Evidence

Current US labeling does not include vitiligo, so a US prescription for it is off-label. Off-label use goes through its own insurance review, separate from an approved use. One commercial insurer’s own published policy shows how that review works for a non-cancer request. It first checks a recognized drug compendium, such as DrugDex. Next it checks a national cancer-drug compendium. Last it checks for a published phase 3 randomized trial. A request that clears none of those steps is denied as experimental or investigational. That same policy treats a Medicare Part D request more narrowly: it accepts only two named compendia there, and a published trial alone does not qualify. Step therapy can still apply after an off-label request is approved. A drug with no FDA approval anywhere, unlike Rinvoq, is not eligible under this kind of policy at all.⌁ Evidence

People I have heard from ask about side effects, and about the boxed warnings, before they ask how well a medicine works. No reader has sent me a first-hand account of Rinvoq for vitiligo yet, and I have no documented pattern of what people taking it describe. I will not invent one. This answer will grow as reader accounts come in.⌁ Evidence

Keep a dated log of each dose and any missed day, plus any new or worsening symptom - especially infection signs. The boxed warnings and monitoring plan above depend on catching those early. Log each screening and lab visit your prescriber sets, since the safety conversation above requires ongoing blood-count, liver, and infection review, not a one-time check. Add a same-conditions photo - same light, distance, and angle - at your first review point, then again near the week-48 mark. That is when the phase 3 studies assessed their result, so a comparison sits against the same timeline the evidence uses.⌁ Evidence⌁ Evidence